Federal Government to Test GenoMed's Approach to the Flu: Could Counter Vaccine Shortage
CONTACT: GenoMed Inc. David W. Moskowitz, MD, MA, FACP (314) 983-9933 dwmoskowitz@genomedics.com
ST. LOUIS, MO. – October 20, 2004 – GenoMed, Inc. (Pink Sheets: GMED), a Next Generation DM™ (Disease Management) company that uses its expertise in genomics to improve clinical outcomes, announced today that the National Institute of Allergy and Infectious Disease (NIAID), a member institute of the National Institutes of Health, has expressed interest in testing GenoMed's novel approach to the flu in an animal model.
GenoMed has applied for patent protection on the use of a class of blood pressure medications in viral diseases, including the flu. This is a totally novel approach. There is no shortage of these medications worldwide.
The federal government has expressed interest in broad-spectrum viral antidotes. GenoMed met last week with federal government officials to discuss GenoMed's potential broad-spectrum viral antidote and further testing of its approach against viral diseases, including influenza.
About GenoMed
GenoMed is leading the clinical revolution which medical genomics has already made possible. GenoMed is currently marketing its protocol for preventing kidney failure due to high blood pressure and diabetes, and delaying emphysema. GenoMed's influenza trial will be Internet-based, like its West Nile virus trial. To enroll in GenoMed's flu trial, click on the "Flu Trial" link at GenoMed's website, www.genomed.com.
. |
